Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Inflammatory Breast Neoplasms × Denosumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 22 Neoplasms 11 Prostatic Neoplasms 8 Multiple Myeloma 8 Neoplasm Metastasis 7 Giant Cell Tumor of Bone 7 Osteoporosis 4 Fractures, Bone 4 Kidney Neoplasms 3 Carcinoma, Renal Cell 3 Carcinoma, Non-Small-Cell Lung 3 Bone Diseases, Metabolic 3 Bone Diseases 3 Spinal Cord Compression 2 Smoldering Multiple Myeloma 2 Recurrence 2 Parathyroid Neoplasms 2 Melanoma 2 Lymphoma 2 Lung Neoplasms 2 Bone Neoplasms 2 Bone Cysts, Aneurysmal 2 With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer Metastatic 1 Paraproteinemias 1 Ovarian Neoplasms 1 Osteosarcoma 1

Interventions

Cyclophosphamide 29 Paclitaxel 19 Epirubicin 18 Trastuzumab 15 Docetaxel 15 Doxorubicin 14 Carboplatin 13 Radiotherapy 12 Filgrastim 10 Taxes 7 Neoadjuvant Therapy 7 pembrolizumab 6 Tamoxifen 6 Capecitabine 6 Albumin-Bound Paclitaxel 6 Thiotepa 5 Peripheral Blood Stem Cell Transplantation 5 Lapatinib 5 Fluorouracil 5 Bevacizumab 5 pertuzumab 4 Granulocyte Colony-Stimulating Factor 4 Cisplatin 4 Chemotherapy, Adjuvant 4 Biopsy 4 130-nm albumin-bound paclitaxel 4 tipifarnib 3 eribulin 3 Surgical Procedures, Operative 3 Specimen Handling 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02682693 2021-02-02

GeparX

GBG Forschungs GmbH

Phase 2 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡